METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation
Esteban A Orellana,Qi Liu,Eliza Yankova,Mehdi Pirouz,Etienne De Braekeleer,Wencai Zhang,Jihoon Lim,Demetrios Aspris,Erdem Sendinc,Dimitrios A Garyfallos,Muxin Gu,Raja Ali,Alejandro Gutierrez,Sigitas Mikutis,Gonçalo J L Bernardes,Eric S Fischer,Allan Bradley,George S Vassiliou,Frank J Slack,Konstantinos Tzelepis,Richard I Gregory
DOI: https://doi.org/10.1016/j.molcel.2021.06.031
2021-08-19
Abstract:The emerging "epitranscriptomics" field is providing insights into the biological and pathological roles of different RNA modifications. The RNA methyltransferase METTL1 catalyzes N7-methylguanosine (m7G) modification of tRNAs. Here we find METTL1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. METTL1 depletion causes decreased abundance of m7G-modified tRNAs and altered cell cycle and inhibits oncogenicity. Conversely, METTL1 overexpression induces oncogenic cell transformation and cancer. Mechanistically, we find increased abundance of m7G-modified tRNAs, in particular Arg-TCT-4-1, and increased translation of mRNAs, including cell cycle regulators that are enriched in the corresponding AGA codon. Accordingly, Arg-TCT expression is elevated in many tumor types and is associated with patient survival, and strikingly, overexpression of this individual tRNA induces oncogenic transformation. Thus, METTL1-mediated tRNA modification drives oncogenic transformation through a remodeling of the mRNA "translatome" to increase expression of growth-promoting proteins and represents a promising anti-cancer target.